It exerts antibacterial activity by inhibiting the synthesis of bacterial cell walls and has antibacterial activity against aerobic Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes) and aerobic Gram-negative bacteria (such as Escherichia coli, Klebsiella pneumoniae, Proteus)

It exerts its antibacterial activity by inhibiting the synthesis of bacterial cell walls, and has antibacterial activity against aerobic Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes) and aerobic Gram-negative bacteria (such as Escherichia coli, Klebsiella pneumoniae, Proteus).

This product belongs to the third generation of cephalosporin, with a broad-spectrum antibacterial effect, and is stable against broad-spectrum beta-lactamases (including penicillinase and cephalosporinase) produced by various Gram-positive and Gram-negative bacteria. This product has a strong antibacterial effect on Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Pseudomonas and Acinetobacter species such as Pseudomonas aeruginosa are less sensitive to this product. Ceftizoxime has a good antibacterial effect on Haemophilus influenzae and Neisseria gonorrhoeae. This product has a poorer effect on Staphylococcus aureus and Staphylococcus epidermidis than the first and second generation cephalosporins. Methicillin-resistant Staphylococcus aureus and Enterococcus are resistant to this product, and various streptococci are highly sensitive to this product. Anaerobic bacteria such as Peptococcus, Peptostreptococcus and some Bacteroides are mostly sensitive to this product, and Clostridium difficile is resistant to this product. 2. The mechanism of action of this product is to achieve bactericidal effect by inhibiting the biosynthesis of bacterial cell wall mucopeptides.

This product is a peripheral analgesic, mainly by inhibiting the synthesis of prostaglandins and other substances that can make pain sensitive to mechanical or chemical stimulation (such as bradykinin, histamine); it may act on the hypothalamus to produce central analgesic effects; the anti-inflammatory mechanism is still unclear, it may be due to the effect of this product on inflamed tissues, by inhibiting the synthesis of prostaglandins or other substances that can cause inflammatory reactions (such as histamine) to play an anti-inflammatory role, inhibition of lysosomal enzyme release and leukocyte chemotaxis may also be related to it; the antipyretic effect may be caused by acting on the hypothalamic temperature regulation center to cause peripheral vasodilation, skin blood Blood flow increases, sweating increases heat dissipation and has an antipyretic effect. This central effect may be related to the inhibition of prostaglandin synthesis in the hypothalamus; it inhibits platelet aggregation by inhibiting platelet cyclooxygenase and reducing prostaglandin production; it can prevent or inhibit cell-mediated immune responses and delayed allergic reactions, reduce the number of T lymphocytes, monocytes, and eosinophils, reduce the binding ability of immunoglobulins to cell surface receptors, and inhibit the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and alleviating the expansion of primary immune responses.

A new generation of macrolide antibiotics, it mainly acts on Gram-positive bacteria, anaerobic bacteria, Chlamydia and Mycoplasma, etc. Its in vitro antibacterial effect is similar to that of erythromycin, and its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.